Prolongation of Survival in Metastatic Melanoma After Active Specific Immunotherapy With a New Polyvalent Melanoma Vaccine

Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma

1988 • 2,196 citations

Experience with the Use of High-Dose Interleukin-2 in the Treatment of 652 Cancer Patients

1989 • 1,003 citations

Treatment of Established Renal Cancer by Tumor Cells Engineered to Secrete Interleukin-4

1991 • 733 citations

Immunological factors which influence response to immunotherapy in malignant melanoma.

1970 • 462 citations

BCG lmmunotherapy of Malignant Melanoma

1974 • 430 citations

Demonstration of antibodies against human malignant melanoma by immunofluorescence.

1968 • 390 citations

A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III).

1983 • 360 citations

Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide.

1986 • 255 citations

Identification of a human neuroectodermal tumor antigen (OFA-I-2) as ganglioside GD2.

1982 • 242 citations

Active specific immunotherapy for melanoma: phase I trial of allogeneic lysates and a novel adjuvant.

1988 • 239 citations

Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients.

1987 • 224 citations

A monoclonal antibody recognizes an O-acylated sialic acid in a human melanoma-associated ganglioside.

1984 • 222 citations

Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2.

1986 • 220 citations

Complications of BCG Immunotherapy in Patients with Cancer

1973 • 215 citations

Ganglioside GM2 as a human tumor antigen (OFA-I-1).

1983 • 174 citations

Prospectively randomized trial of adjuvant active‐specific immunotherapy for human colorectal cancer

1985 • 164 citations

Surgical Resection and Adjunctive lmmunotherapy for Selected Patients with Multiple Pulmonary Metastases

1973 • 142 citations

Modulation of Suppressor-Cell Activity by Cimetidine in Patients with Common Variable Hypogammaglobulinemia

1985 • 141 citations

Prolonged Survival for Melanoma Patients With Elevated IgM Antibody to Oncofetal Antigen<xref ref-type="fn" rid="fn2">2</xref><xref ref-type="fn" rid="fn3">3</xref>

1981 • 126 citations

Rapid assay for evaluating the chemosensitivity of human tumors in soft agar culture.

1982 • 124 citations

Complete responses and long-term survivals after systemic chemotherapy for patients with advanced malignant melanoma

1989 • 105 citations

Primary but not metastatic human melanomas expressing dr antigens stimulate autologous lymphocytes

1984 • 104 citations

Inhibition of T suppressor cell expression by histamine type 2 (H2) receptor antagonists.

1984 • 96 citations

HLA-DR histocompatibility leukocyte antigens permit cultured human melanoma cells from early but not advanced disease to stimulate autologous lymphocytes.

1984 • 96 citations

Variations in functional immunocompetence of individual tumor-draining lymph nodes in humans.

1987 • 83 citations

Modulation of human melanoma cells by interleukin-4 and in combination with gamma-interferon or alpha-tumor necrosis factor.

1991 • 76 citations

Immunization with haptenized, autologous tumor cells induces inflammation of human melanoma metastases.

1991 • 76 citations

Suppressor cell activity in a randomized trial of patients receiving active specific immunotherapy with melanoma cell vaccine and low dosages of cyclophosphamide.

1990 • 75 citations

An epitope common to gangliosides O-acetyl-GD3 and GD3 recognized by antibodies in melanoma patients after active specific immunotherapy.

1989 • 67 citations

A southeastern cancer study group phase I/II trial with vaccinia melanoma oncolysates

1986 • 65 citations

Interleukin 4 alone and with gamma-interferon or alpha-tumor necrosis factor inhibits cell growth and modulates cell surface antigens on human renal cell carcinomas.

1991 • 64 citations

Immunogenicity of a polyvalent melanoma antigen vaccine in humans

1988 • 62 citations

Combination tumor‐immunotherapy with recombinant tumor necrosis factor and recombinant interleukin 2 in mice

1987 • 57 citations

PRELIMINARY RESULTS OF A RANDOMIZED TRIAL OF ADJUVANT IMMUNOTHERAPY IN PATIENTS WITH MALIGNANT MELANOMA WHO HAVE LYMPH NODE METASTASES

1978 • 45 citations

Induction of antibodies to a tumor-associated antigen by immunization with a whole melanoma cell vaccine

1989 • 44 citations

Treatment for melanoma of the lower extremity with intralesional injection of bacille Calmette Guérin and hyperthermic perfusion.

1979 • 42 citations

Active specific immunotherapy in malignant melanoma

1989 • 41 citations

Active immunotherapy against cancer: present status.

1986 • 39 citations

Inhibition of suppressor-cell activity by cyclophosphamide in patients with malignant melanoma.

1987 • 33 citations

Cis-dichlorodiammineplatinum(II) alone and combined with DTIC for treatment of disseminated malignant melanoma.

1979 • 31 citations

Active specific immunotherapy with vaccinia colon oncolysate enhances the immunomodulatory and antitumor effects of interleukin-2 and interferon α in a murine hepatic metastasis model

1990 • 30 citations

Induction of CD4+ cytotoxic T cells by sensitization with allogeneic melanomas bearing shared or cross-reactive HLA-A

1992 • 28 citations

Role of Gangliosides in Active Immunotherapy with Melanoma Vaccine

1991 • 28 citations

Immunochemical characterization of fetal antigen isolated from spent medium of a human melanoma cell line.

1983 • 27 citations

Effect of continuous administration of interleukin 2 on active specific chemoimmunotherapy with extracted tumor-specific transplantation antigen and cyclophosphamide.

1988 • 27 citations

Prostaglandins and the immune response to cancer (review).

1981 • 27 citations

Establishment of paired tumor cells and autologous virus‐transformed cell lines to define humoral immune responses in melanoma and sarcoma patients

1978 • 26 citations

Modulation of Histamine Type II Receptors on CD8+ T Cells by lnterleukin-2 and Cimetidine

1992 • 24 citations

Studies of a Melanoma Tumor-Associated Antigen Detected in the Spent Culture Medium of a Human Melanoma Cell Line by Allogeneic Antibody. I. Purification and Development of a Radioimmunoassay23

1984 • 19 citations

Cytotoxic T cell lines recognize autologous and allogeneic melanomas with shared or cross-reactive HLA-A

1992 • 17 citations

Clinical-biologic patterns of metastatic melanoma and their effect on treatment.

1985 • 15 citations

Rejection of dinitrochlorobenzene-conjugated syngeneic tumor cells by dinitrochlorobenzene-sensitized guinea pigs

1978 • 7 citations

Prognostic significance of cutaneous anergy for the surgical treatment of solid neoplasms.

1971 • 6 citations

Electrocardiogram studies on cancer patients treated with OK-432, a streptococcal preparation with potent biological response modifier activities.

1989 • 2 citations